Metastatic bone disease: role of transcription factors and future targets. - Wikidata - wikimedia - TriplyDB

Metastatic bone disease: role of transcription factors and future targets.

Metastatic bone disease: role of transcription factors and future targets.

http://www.wikidata.org/entity/Q34217531

about

RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment Role of RUNX2 in Breast Carcinogenesis SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2 RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland.MicroRNAs in the control of metastatic bone disease.hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3.GPRC6A regulates prostate cancer progression A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes DNA-binding small molecules as inhibitors of transcription factors.Runx2-Smad signaling impacts the progression of tumor-induced bone disease Subnuclear domain proteins in cancer cells support the functions of RUNX2 in the DNA damage response.Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1 Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion.Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells.RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.Transcription factor networks in invasion-promoting breast carcinoma-associated fibroblasts.Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF-β-signaling pathway: The Breast Cancer Health Disparities Study.Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.Molecular targets for radiation oncology in prostate cancer.The RUNX family in breast cancer: relationships with estrogen signaling.RUNX2 in mammary gland development and breast cancer.Bone tissue engineering and regenerative medicine: targeting pathological fractures.Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Runx3 in Immunity, Inflammation and Cancer.Runx2 and microRNA regulation in bone and cartilage diseases.

P2860

Q26800112-BCB84E19-F68F-4133-8059-E2821B337295 Q26865458-9C63E4B5-EE55-47F6-88B5-186DFCB154E4 Q28084968-E42AAD9A-4618-41B4-9B2F-9BFABBE49F52 Q28237131-0092F091-CB82-4B9E-A38A-C4F29221EEBE Q28505869-5102335F-AEB7-4860-B296-9E05E5516584 Q33555996-DE721E06-6120-4385-B72D-ACEE86033077 Q33821326-3A655196-0569-41C0-A0F9-8E324B85F809 Q34031000-A5B940C9-AFC5-4FDC-80D6-ED27D5B66361 Q34193432-431E4E0B-36A4-4E1B-8E4E-0D4E16DEFA16 Q34203659-6BFDAD14-E681-407E-83D9-6A8F2BD90C16 Q34253203-F380D700-6B67-4CF3-831B-25B38D7858A9 Q34898865-0B2B14B8-1612-41F4-8E01-20B9EFC876F8 Q35081686-296D4961-6F60-47A0-9E64-F335D10B0C1C Q35251618-D9A74261-AB33-4D23-BD2D-710FEB06A94B Q35751787-393B461C-6D08-4C86-804C-100B88E043EC Q35762938-3568F6AD-CF84-48AF-ABAB-CD262FD08EC7 Q35782827-E06DC764-6868-402A-A9B1-EB4C05D95A6A Q35889495-14C5814E-3DE5-4B4E-B972-8B093156720E Q35889648-50489A91-EC97-4702-8E25-0F9E372885D0 Q35906122-4CD13710-370D-4AE1-AC6D-E74A290EF36D Q36040069-AA21B6AD-CB56-4D86-A288-77D7A4ABAAD9 Q36637143-8063CE23-E3DB-4A6A-A789-49238A84BA58 Q36695058-DCE7C4C7-E5FA-42C6-A1CB-603CD5709ED3 Q36937029-A312D44B-A47F-4685-9230-AB3911936DEF Q37175182-652EC5CC-1BBF-4574-9E65-1EC9BA77A8BB Q37187646-BA5740E3-FDA9-401A-8F85-85D5E86D7B16 Q37604399-C235795B-D051-441D-A9CF-4D014B2AE9B1 Q37624119-B0C8BDE8-4A4F-4E86-9EEF-FBCE9018299A Q37625382-48FB9854-D509-4738-8BAA-849252607AE5 Q37688549-670BBCF2-4232-4389-BF49-585651D2BD73 Q37691008-8B6EF79B-3592-4DC6-8E0E-8B069A051886 Q37694746-486571BE-8827-4BD8-ADA8-C7E9DFDE7E1D Q37744995-C5CCCFF4-77CE-4ECB-AD0E-FF6E420464DE Q38014447-ADDAFBE5-BBB7-472C-AC04-B9CB2D0A0400 Q38050410-459534E6-931E-447D-8B32-611270F7421F Q38061373-3E8A38BD-0C7F-42DE-AD71-F9413CC7732F Q38200041-D82C2253-7B5E-43CA-B8D9-4FF465EA8B09 Q38722836-531C4D2C-95E2-4B08-B468-7EC7DD08FCF1 Q38904246-99D826AF-C9C4-4605-829B-1A84E6AB302B Q38928077-5B9F625D-A755-4E28-9FE0-4D80D097F911

P2860

Metastatic bone disease: role of transcription factors and future targets.

http://www.wikidata.org/entity/Q34217531

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Metastatic bone disease: role of transcription factors and future targets.

@ast

Metastatic bone disease: role of transcription factors and future targets.

@en

Metastatic bone disease: role of transcription factors and future targets.

@nl

type

label

Metastatic bone disease: role of transcription factors and future targets.

@ast

Metastatic bone disease: role of transcription factors and future targets.

@en

Metastatic bone disease: role of transcription factors and future targets.

@nl

prefLabel

Metastatic bone disease: role of transcription factors and future targets.

@ast

Metastatic bone disease: role of transcription factors and future targets.

@en

Metastatic bone disease: role of transcription factors and future targets.

@nl

P1433

Q34217531-165B3A3A-8F0E-4D5F-BDB0-5438B19FEC84

P1476

Q34217531-5CD0E7EF-8E47-456F-A8AC-6A5E064FD9F6

P2093

Q34217531-0C08849D-C14C-4BE1-933F-1133CB755C93

Q34217531-9DBE9318-23B7-433C-9BFF-74360C9B95A0

Q34217531-D76512E5-5193-47DF-9E6F-4A98ACA56E46

P2860

Q34217531-04A9B4CD-AB4C-45E1-B4A2-9BE61664BE4A

Q34217531-08844E6C-8CCD-4A3B-A5A0-452ED49C8DDC

Q34217531-09A4E408-6DBE-4E10-BFBD-B05A690C6C7D

Q34217531-0A7BC24E-190C-450A-B905-001C4FE4DF79

Q34217531-0C370E45-E12D-4136-B9A8-321550C07B7D

Q34217531-0FB0AAAE-F394-47AC-9F9C-8CAA80FCABCA

Q34217531-15DF36CC-1959-4C57-A549-2AACE1873FA2

Q34217531-18652020-B128-470B-B6A4-C8A93277A521

Q34217531-23D70989-C591-42C6-88FB-576B519EA33D

Q34217531-244A2F2E-6723-4E1C-BD0F-C8AA783E8755

P304

Q34217531-0DBD8DA1-3570-4D1E-94BE-A1F418D4C07E

P31

Q34217531-9907EFEB-12A7-4B07-BC67-41EF0EF9A886

P356

Q34217531-632ED1D1-E15B-4570-9003-7D4C5C97B5AD

P433

Q34217531-E1637E7A-1F94-4520-97E0-DCD68467A842

P478

Q34217531-B5FF3719-4BB0-4E0E-977B-268EA35F250F

P577

Q34217531-22523DCC-7AA8-436F-A94E-650D097F58E0

P5875

Q34217531-9FDC531C-5804-4545-8DBF-378363829530

P698

Q34217531-71E2DA79-7D50-49CD-91A4-355A04ED70E7

P932

Q34217531-94BD0922-A4D0-4A69-B1D1-06F71DBB65AA

P356

J.BONE.2010.05.035

P1433

P1476

Metastatic bone disease: role of transcription factors and future targets.

@en

P2093

Gary S Stein

http://www.w3.org/2001/XMLSchema#string

Jane B Lian

http://www.w3.org/2001/XMLSchema#string

Jitesh Pratap

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes

Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA

Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemia

A microRNA signature for a BMP2-induced osteoblast lineage commitment program

A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis

Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer

Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development

Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells

The RUNX genes: gain or loss of function in cancer

Causes and consequences of microRNA dysregulation in cancer

P304

30-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BONE.2010.05.035

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44686539

http://www.w3.org/2001/XMLSchema#string

P698

20561908

http://www.w3.org/2001/XMLSchema#string

P932

2958222

http://www.w3.org/2001/XMLSchema#string